Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-24T23:56:17.210Z Has data issue: false hasContentIssue false
  • English
  • Français

FETAL EFFECTS OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR TREATMENT DURING PREGNANCY: IMMEDIATE AND LONGER TERM CHILD OUTCOMES

Published online by Cambridge University Press:  10 October 2012

REBECCA L BROMLEY ,
ANGELIKA WIECK ,
DARIA MAKAROVA ,
CLARE TOWER ,
AMANDA WOOD  and
JILL CLAYTON-SMITH
REBECCA L BROMLEY*
Affiliation:
Division of Clinical Psychology, School of Psychological Science, University of Manchester.
ANGELIKA WIECK
Affiliation:
Department of Psychiatry, Manchester Mental Health and Social Care Trust.
DARIA MAKAROVA
Affiliation:
School of Psychology, University of Birmingham.
CLARE TOWER
Affiliation:
Maternal and Fetal Health Research Centre, Manchester Academic Health Sciences Centre.
AMANDA WOOD
Affiliation:
School of Psychology, University of Birmingham.
JILL CLAYTON-SMITH
Affiliation:
Genetic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre. Department of Biomedical Science, University of Manchester.
*
Dr Rebecca Bromley, Division of Clinical Psychology, School of Psychological Science, University of Manchester, Oxford road, Manchester M13 9PLUnited Kingdom Email: rebeccalbromley@googlemail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Review Article
Information
Fetal and Maternal Medicine Review , Volume 23 , Issue 3-4 , November 2012 , pp. 230 - 275
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1Bennett, HA, Einarson, TR. Depressive Symptoms among Women Screened in Obstetrics Settings. J Women's Health 2004; 13: 119.Google Scholar
2Ververs, T, Kaasenbrood, H, Visser, G, Schobben, F, de Jong-van den Berg, L, Egberts, T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006; 62: 863–70.CrossRefGoogle ScholarPubMed
3Andrade, SE, Raebel, MA, Brown, J, Lane, K, Livingston, J, Boudreau, D, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198: 1–5.Google Scholar
4Bakker, MK, Kolling, P, van den Berg, PB, de Walle, HE, de Jong van den Berg, LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008; 65: 600–606.Google Scholar
5Petersen, I, Gilbert, RE, Evans, SJ, Man, SL, Nazareth, I. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psych 2011; 72: 979–85.Google Scholar
6Noorlander, CW, Ververs, FFT, Nikkels, PGJ, van Echteld, CJA, Visser, GHA, Smidt, MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS ONE. 2008; 3: e2782.CrossRefGoogle ScholarPubMed
7Hale, TW, Kendall-Tackett, K, Cong, Z, Votta, R, McCurdy, F. Discontinuation syndrome in newborns whose mothers took antidepressants while pregnant or breastfeeding. Breastfeed Med 2010; 5: 283–88.Google Scholar
8Loughhead, AM, Fisher, AD, Newport, DJ, Ritchie, JC, Owens, MJ, DeVane, CL, Stowe, ZN. Antidepressants in amniotic fluid: another route of fetal exposure? Am J Psych 2006; 163: 145–47.Google Scholar
9Rodier, PM. Environmental Causes of Central Nervous System Maldevelopment. Pediatrics 2004; 113: 1076–83.Google Scholar
10Grote, NK, Bridge, JA, Gavin, AR, Melville, JL, Iyengar, S, Katon, WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psych 2010; 67: 1012–1024.Google Scholar
11Deave, T, Heron, J, Evans, J, Emond, A. The impact of maternal depression in pregnancy on early child development. Br J Obstet Gynecol 2008; 115: 1043–51.CrossRefGoogle ScholarPubMed
12DiPietro, JA, Novak, MF, Costigan, KA, Atella, LD, Reusing, SP. Maternal psychological distress during pregnancy in relation to child development at age two. Child Dev 2006; 77: 573–87.Google Scholar
13Goodman, SH, Gotlib, IH. Risk for psychopathology in the children of depressed mothers: A developmental model for understanding mechanisms of transmission. Psychol Rev 1999; 106: 458–90.Google Scholar
14Thomas, DR, Hagan, JJ. 5-HT7 receptors. Current Drug Targets CNS and Neurol Disord 2004; 3: 81–90.CrossRefGoogle ScholarPubMed
15Homberg, JR, Schubert, D, Gaspar, P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 2010; 31: 60–65.Google Scholar
16Wells, GA, Shead, B, O'Connell, D, Peterson, J, Welch, V, Losos, M, Tugwell, P. The Newcastle Ottata Scale. http://www.lri.ca/programs/ceu/oxford.htm.2008.Google Scholar
17Adab, N, Tudur, SC, Vinten, J, Williamson, P, Winterbottom, J. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane database of systematic reviews (Online). 2004: CD004848.Google Scholar
18Beckman, DA BR. Mechanisms of teratogenesis. Ann Rev Pharmacol Toxicol 1984; 24: 483–500.Google Scholar
19Simon, GE, Cunningham, ML, Davis, RL. Outcomes of prenatal antidepressant exposure. Am J Psych 2002; 159: 2055–2061.Google Scholar
20Casper, RC, Gilles, AA, Fleisher, BE, Baran, J, Enns, G, Lazzeroni, LC. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: Effects on neonatal adaptation and psychomotor development. Psychopharmacol 2011; 217: 211–19.Google Scholar
21Lund, N, Pedersen, LH, Henriksen, TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes: Arch Pediatr Adolesc Med 2009; 163: 949–54.CrossRefGoogle ScholarPubMed
22Oberlander, TF, Warburton, W, Misri, S, Aghajanian, J, Hertzman, C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants. Population-based study. Br J Psych 2008; 192: 338–43.Google Scholar
23Rampono, J, Simmer, K, Ilett, KF, Hackett, LP, Doherty, DA, Elliot, R, et al.Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009; 42: 95–100.Google Scholar
24Roca, A, Garcia-Esteve, L, Imaz, ML, Torres, A, Hernandez, S, Botet, F, et al.Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors. The relevance of dose. J Affect Disord 2011; 135: 208–15.Google Scholar
25Kallen, B. Neonate Characteristics after Maternal Use of Antidepressants in Late Pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312–16.Google Scholar
26Wisner, KL, Sit, DK, Hanusa, BH, Moses-Kolko, EL, Bogen, DL, Hunker, DF, et al.Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psych 2009; 166: 557–66.Google Scholar
27Davis, RL, Rubanowice, D, McPhillips, H, Raebel, MA, Andrade, SE, Smith, Det al.for the HMO Research Network Centre for Education, Research in Therapeutics. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiology Drug Saf 2007; 16: 1086–94.Google Scholar
28Davidson, S, Prokonov, D, Taler, M, Maayan, R, Harell, D, Gil-Ad, I, et al.Effect of exposure to selective serotonin reuptake inhibitors. In Utero on fetal growth: Potential role for the IGF-I and HPA axes. Ped Res 2009; 65: 236–41.Google Scholar
29Hendrick, V, Smith, LM, Suri, R, Hwang, S, Haynes, D, Altshuler, L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003; 188: 812–15.Google Scholar
30Malm, H, Klaukka, T, Neuvonen, PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106: 1289–296.Google Scholar
31Nordeng, H, Van Gelder, MMHJ, Spigset, O, Koren, G, Einarson, A, Eberhard-Gran, M. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: Results from the Norwegian mother and child cohort study. J Clin Psychopharmacol 2012; 32: 186–194.Google Scholar
32Pearson, KH, Nonacs, RM, Viguera, AC, Heller, VL, Petrillo, LF, Brandes, M, et al.Birth outcomes following prenatal exposure to antidepressants. J Clin Psych 2007; 68: 1284–289.CrossRefGoogle ScholarPubMed
33Sit, D, Perel, JM, Wisniewski, SR, Helsel, JC, Luther, JF, Wisner, KL. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. J Clin Psych 2011; 72: 994–1001.Google Scholar
34Toh, S, Mitchell, AA, Louik, C, Werler, MM, Chambers, CD, Hernandez-Diaz, S. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 2009; 29: 555–60.Google Scholar
35Costei, AM, Kozer, E, Ho, T, Ito, S, Koren, G. Perinatal outcome following third trimester exposure to paroxetine. Arch Ped Adolesc Med 1129; 156: 1129–132.CrossRefGoogle Scholar
36Chambers, CD, Johnson, KA, Dick, LM, Felix, RJ, Jones, KL. Birth outcomes in pregnant women taking fluoxetine. New Engl J Med 1996; 335: 1010–1015.Google Scholar
37Cohen, LS, Heller, VL, Bailey, JW, Grush, L, Ablon, J, Bouffard, SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psych 2000; 48: 996–1000.Google Scholar
38Pastuszak, A, Schick-Boschetto, B, Zuber, C, Feldkamp, M, Pinelli, M, Sihn, S, et al.Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246–248.Google Scholar
39Suri, R, Altshuler, L, Hendrick, V, Rasgon, N, Lee, E, Mintz, J. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Women's Ment Health 2004; 7: 193–200.Google Scholar
40Sivojelezova, A, Shuhaiber, S, Sarkissian, L, Einarson, A, Koren, G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 2004; 193: 2004–2009.CrossRefGoogle Scholar
41Oberlander, TF, Warburton, W, Misri, S, Aghajanian, J, Hertzman, C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psych 2006; 63: 898–906.Google Scholar
42Oberlander, T, Bonaguro, R, Misri, S, Papsdorf, M, Ross, C, Simpson, E. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psych 2008; 13: 65–73.Google Scholar
43Ericson, A, Kallen, B, Wiholm, B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 503–508.Google Scholar
44Diav-Citrin, O, Shechtman, S, Weinbaum, D, Wajnberg, R, Avgil, M, Di Gianantonio, E, et al.Paroxetine and fluoxetine in pregnancy: A prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008; 66: 695–705.CrossRefGoogle ScholarPubMed
45Jordan, AE, Jackson, GL, Deardorff, D, Shivakumar, G, McIntire, DD, Dashe, JS. Serotonin reuptake inhibitor use in pregnancy and the neonatal behavioral syndrome. J Mat Fetal Neonatal Med 2008; 21: 745–51.Google Scholar
46Laine, K, Heikkinen, T, Ekblad, U, Kero, P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psych 2003; 60: 720–26.Google Scholar
47Levinson-Castiel, R, Merlob, P, Linder, N, Sirota, L, Klinger, G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160: 173–76.Google Scholar
48Sanz, EJ, De-las-Cuevas, C, Kiuru, A, Bate, A, Edwards, R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: A database analysis. Lancet 2005; 365: 482–87.Google Scholar
49Zeskind, PS, Stephens, LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113: 368–75.Google Scholar
50Casper, RC, Fleisher, BE, Lee-Ancajas, JC, Gilles, A, Gaylor, E, DeBattista, A, et al.Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142: 402–408.Google Scholar
51Warburton, W, Hertzman, C, Oberlander, TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psych Scand 2010; 121: 471–79.Google Scholar
52Andrade, SE, McPhillips, H, Loren, D, Raebel, MA, Lane, K, Livingston, J, et al.Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepide Drug Saf 2009; 18: 246–52.Google Scholar
53Chambers, CD, Hernandez-Diaz, S, Van Marter, LJ, MM, Werler, Louik, C, Jones, KL, et al.Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med 2006; 354: 579–87.CrossRefGoogle ScholarPubMed
54Kallen, B, Olausson, PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepide Drug Saf 2008; 17: 801–806.Google Scholar
55Kieler, H, Artama, M, Engeland, A, Ericsson, O, Furu, K, Gissler, M, et al.Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344: d8012.Google Scholar
56Reis, M, Kallen, B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723–733.Google Scholar
57Wichman, CL, Moore, KM, Lang, TR, St Sauver, JL, Heise, Jr RH, Watson, WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy: Mayo Clinic proceedings. Mayo Clinic 2009; 84: 23–27.Google Scholar
58Alwan, S, Reefhuis, J, Rasmussen, SA, Olney, RS, Friedman, JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. New Engl J Med 2007; 356: 2684–692.CrossRefGoogle ScholarPubMed
59Einarson, A, Choi, J, Einarson, TR, Koren, G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: Results of a large prospective cohort study. Can J Psych 2009; 54: 242–46.Google Scholar
60Kallen, BA, Otterblad Olausson, P.Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations: Birth Defects Res A Clin Mol Teratol 2007; 79: 301–308.Google Scholar
61Kulin, NA, Pastuszak, A, Sage, SR, Schick-Boschetto, B, Spivey, G, Feldkamp, M, et al.Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study. JAMA 1998; 279: 609–10.Google Scholar
62Louik, C, Lin, AE, Werler, MM, Hernandez-Diaz, S, Mitchell, AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. New Engl J Med 2007; 356: 2675–683.Google Scholar
63Malm, H, Artama, M, Gissler, M, Ritvanen, A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011; 118: 111–20.CrossRefGoogle ScholarPubMed
64Oberlander, TF, Warburton, W, Misri, S, Riggs, W, Aghajanian, J, Hertzman, C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Research Part B - Dev Reprod Toxicol 2008; 83: 68–76.Google Scholar
65Pedersen, LH, Henriksen, TB, Vestergaard, M, Olsen, J, Bech, BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339: b3569.Google Scholar
66Ramos, E, St-Andre, M, Rey, E, Oraichi, D, Berard, A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008; 192: 344–50.Google Scholar
67Kornum, JB, Nielsen, RB, Pedersen, L, Mortensen, PB, Norgaard, M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: Updated analysis. Clin Epidemiol 2010; 2: 29–36.Google Scholar
68Wogelius, P, Norgaard, M, Gislum, M, Pedersen, L, Munk, E, Mortensen, PB, et al.Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006; 17: 701–704.Google Scholar
69Merlob, P, Birk, E, Sirota, L, Linder, N, Berant, M, Stahl, B, et al.Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009; 85: 837–41.Google Scholar
70Dubnov-Raz, G, Juurlink, DN, Fogelman, R, Merlob, P, Ito, S, Koren, G, et al.Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 2008; 122: e710–715.Google Scholar
71Goldstein, DJ, Corbin, LA, Sundell, KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89: 713–18.Google Scholar
72Bakker, MK, De Walle, HE, Wilffert, B, de Jong-Van den Berg, LT. Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study. Pharmacoepidemiology Drug Saf 2010; 19: 808–13.Google Scholar
73Cole, JA, Ephross, SA, Cosmatos, IS, Walker, AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiology Drug Saf 2007; 16: 1075–85.CrossRefGoogle ScholarPubMed
74Berard, A, Ramos, E, Rey, E, Blais, L, St.-Andre, M, Oraichi, D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage: Birth Defects Research Part B – Dev Reprod Toxicol 2007; 80: 18–27.Google Scholar
75Bakker, MK, Kerstjens-Frederikse, WS, Buys, CHCM, De Walle, HEK, De Jong-van Den Berg, LTW. First-trimester use of paroxetine and congenital heart defects: A population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010; 88: 94–100.CrossRefGoogle ScholarPubMed
76Einarson, A, Pistelli, A, DeSantis, M, Malm, H, Paulus, WD, Panchaud, A, et al.Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psych 2008; 165: 749–52.Google Scholar
77Croen, LA, Grether, JK, Yoshida, CK, Odouli, R, Hendrick, V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psych 2011;.68: 1104–112.Google Scholar
78Mulder, EJH, Ververs, FFT, De Heus, R, Visser, GHA. Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacology 2011; 36: 1961–1971.Google Scholar
79Oberlander, TF, Papsdorf, M, Brain, UM, Misri, S, Ross, C, Grunau, RE. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch Ped Adolesc Med 2010; 164: 444–51.Google Scholar
80Pedersen, LH, Henriksen, TB, Olsen, J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010; 125: e600–608.Google Scholar
81Salisbury, AL, Wisner, KL, Pearlstein, T, Battle, CL, Stroud, L, Lester, BM. Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment. Depress Anxiety 2011; 28: 1008–1019.Google Scholar
82Klinger, G, Frankenthal, D, Merlob, P, Diamond, G, Sirota, L, Levinson-Castiel, R, et al.Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol 2011; 31: 615–20.Google Scholar
83Oberlander, TF, Reebye, P, Misri, S, Papsdorf, M, Kim, J, Grunau, RE. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Ped Adolesc Med 2007; 161: 22–29.Google Scholar
84Misri, S, Reebye, P, Kendrick, K, Carter, D, Ryan, D, Grunau, RE, et al.Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psych 2006; 163: 1026–1032.Google Scholar
85Figueroa, R. Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring: J Dev Behav Pediatr 2010; 31: 641–48.Google Scholar
86Heikkinen, T, Ekblad, U, Kero, P, Ekblad, S, Laine, K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72: 184–91.Google Scholar
87Nulman, I, Rovet, J, Stewart, DE, Wolpin, J. Neurodevelopment of children exposed in utero to antidepressant drugs. New Engl J Med 1997; 336: 258–62.CrossRefGoogle ScholarPubMed
88Nulman, I, Rovet, J, Stewart, DE, Wolpin, J, Pace-Asciak, P, Shuhaiber, S, et al.Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: A prospective, controlled study. Am J Psych 2002; 159: 1889–1895.Google Scholar
89Bar-Oz, B, Einarson, T, Einarson, A, Boskovic, R, O'Brien, L, Malm, H, et al.Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factors. Clin Therap 2007; 29: 918–26.Google Scholar
90Wurst, KE, Poole, C, Ephross, SA, Olshan, AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 201; 88: 159–70.Google Scholar
91O'Brien, L, Einarson, TR, Sarkar, M, Einarson, A, Koren, G. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can 2008; 30: 696–701.Google Scholar
92Holmes, LB, Hernandez-Diaz, S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol 22 June doi: 10.1002/bdra.23028. [epub ahead of print].Google Scholar
93Einarson, A, Selby, P, Koren, G. Abrupt discontinuation of psychotropic drugs during pregnancy: Fear of teratogenic risk and impact of counselling. J Psych Neurosci 2001; 26: 44–48.Google Scholar
94Tomson, T, Battino, D, Bonizzoni, E, Craig, J, Lindhout, D, Sabers, A, et al.Dose-dependent risk of malformations with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10: 609–17.Google Scholar
95Stiles, J.The fundamentals of brain development: integrating nature and nurture. Cambridge, Massachusetts: Harvard University Press; 2008.Google Scholar
96Pawluski, JL. Perinatal serotonin reuptake inhibitor exposure: impact on brain development and neural plasticity. Neuroendocrinol 2012; 95: 39–46.Google Scholar
97Cohen, J. A power primer. Psychological Bulletin. 1992; 112: 155–59.Google Scholar
98Moyers, S, Bailey, LB. Fetal malformations and folate metabolism: review of recent evidence. Nutrition Rev 2001; 59: 215–24.Google Scholar